Brief: Akari Therapeutics Provides Update On Development Of PAS-Nomacopan
11/07/2023 13:14
July 11 (Reuters) - Akari Therapeutics PLC AKTX.O :
* AKARI THERAPEUTICS PROVIDES UPDATE ON DEVELOPMENT OF
LONG-ACTING
PAS-NOMACOPAN FOR TREATMENT OF GEOGRAPHIC ATROPHY
* AKARI THERAPEUTICS PLC - REMAINS ON TRACK FOR AN IND
SUBMISSION
IN FIRST HALF OF 2024 AND START OF CLINICAL TRIALS IN SECOND
HALF OF 2024
* AKARI THERAPEUTICS PLC - HAS SELECTED WACKER BIOTECH GMBH
AS
MANUFACTURING PARTNER TO SUPPORT PRODUCTION OF PAS-NOMACOPAN FOR
USE IN CLINICAL TRIALS
Source text for Eikon: ID:nGNE7Vl4gQ
Further company coverage: AKTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics